An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3

✍ Scribed by Murakami, H.; Kurata, T.; Onozawa, Y.; Watanabe, J.; Ono, A.; Takahashi, T.; Yamamoto, N.; Fujisaka, Y.; Kiyota, H.; Hayashi, H.; Tanaka, K.; Nakagawa, K.; Kuroda, S.

• Book ID: 121544949
• Publisher: Springer
• Year: 2014
• Tongue: English
• Weight: 474 KB
• Volume: 73
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-014-2388-x